Compare NTRA & TRGP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NTRA | TRGP |
|---|---|---|
| Founded | 2003 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Natural Gas Distribution |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.7B | 56.8B |
| IPO Year | 2015 | 2010 |
| Metric | NTRA | TRGP |
|---|---|---|
| Price | $272.94 | $278.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 23 | 22 |
| Target Price | ★ $412.36 | $333.48 |
| AVG Volume (30 Days) | ★ 2.0M | 1.2M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 1.75% |
| EPS Growth | 0.65 | ★ 47.91 |
| EPS | N/A | ★ 8.79 |
| Revenue | $210,939,000.00 | ★ $17,028,300,000.00 |
| Revenue This Year | $30.72 | $14.52 |
| Revenue Next Year | $21.67 | $20.67 |
| P/E Ratio | ★ N/A | $32.47 |
| Revenue Growth | N/A | ★ 3.95 |
| 52 Week Low | $181.00 | $167.12 |
| 52 Week High | $437.41 | $316.60 |
| Indicator | NTRA | TRGP |
|---|---|---|
| Relative Strength Index (RSI) | 24.66 | 43.12 |
| Support Level | $254.83 | $272.07 |
| Resistance Level | $288.04 | $296.88 |
| Average True Range (ATR) | 19.03 | 10.22 |
| MACD | -7.70 | -0.82 |
| Stochastic Oscillator | 1.47 | 45.76 |
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Targa Resources Corp is a midstream firm that mainly operates gathering and processing assets with substantial positions in the Permian, Stack, Scoop, and Bakken plays. It has fractionation capacity at Mont Belvieu and operates a liquefied petroleum gas export terminal. The Grand Prix natural gas liquids pipeline is another important asset. It has two operating segments: Gathering and Processing, and, Logistics and Transportation (also referred to as the Downstream Business).